InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$25.28

2026-10-16

Market Cap

$13.1B

Volume

4.4M

52-Wk High

$30.00

52-Wk Low

$15.73

Trailing PE

-12.4

P/S

1.14

Gross Margin

30.1%

Net Margin

-9.3%

ROE

-17%

ROIC

-2%

Piotroski

4/9

Altman Z

2.3

1-Yr Return

+10.3%

5-Yr Return

-67.1%

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

SectorHealthcareIndustryMedical - Instruments & SuppliesExchangeNYSEMarket Cap$13.1BEmployees37,500 (SEC-filed)CEOAndrew HiderIPO1981-10-27CountryUS

One Baxter Parkway, Deerfield, IL 60015 · Tel 224 948 2000 · baxter.com

INSIDERSTREET SCORE32 / 100Street mean $24.25 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALCOMP-PLAN ACTIVITY ONLYexercises and tax withholding only

1 Year vs S&P 500 · BAX +10.3% · S&P 500 +15.9% · spread -5.6pp

7 Years vs S&P 500 · BAX -67.1% · S&P 500 +189.9% · spread -256.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE32of 100

Score Breakdown

Profitability	18/100
Growth	37/100
Momentum	38/100
Quality	33/100
Earnings Quality	43/100
Balance Sheet	34/100
Value	39/100
Risk (safety)	50/100
Overall	31.8/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
SOLV	37
RGEN	64
AVTR	20
COO	69
HOLX	56
ATR	55
BAX	32

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 52 in 23 Q3, latest 32 — -20 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY32 / 100IS Score 31.8 / 100 · -20.4 from peak of 52

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 81 / 100 · Power +62 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 32, price structure 81 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 31.8	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 23 → 26 → 33 → 32	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 945 → now 694	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-05-01

Insider Buys (180d)0none disclosed

ETF Funds (30d)551 up / 401 downnet +150 funds

Institutions Added (13F)29managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 945 · latest 694 (-251 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	694	562.6M	$11.8B	108.8%
2026 Q1	665	529.1M	$8.9B	102.3%
2025 Q4	714	550.7M	$10.5B	106.5%
2025 Q3	736	506.7M	$11.6B	98.0%
2025 Q2	779	497.8M	$14.2B	96.3%
2025 Q1	846	491.7M	$16.0B	95.1%
2024 Q4	830	482.7M	$13.9B	93.4%
2024 Q3	903	465.7M	$17.7B	90.1%
2024 Q2	886	455.7M	$15.0B	88.1%
2024 Q1	945	454.2M	$18.8B	87.8%
2023 Q4	919	458.1M	$17.5B	88.6%
2023 Q3	910	448.0M	$16.8B	86.6%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Hider Andrew P.	director, President and CEO	2026-09-02	TAX W/H	54,276	$1.39M	518,447
Foster Julie	President, Front Line Care	2026-09-02	TAX W/H	2,098	$0.05M	29,164
Wilkes David S.	director	2026-05-05	A-Award	12,836	—	37,076
Wendell Amy Mcbride	director	2026-05-05	A-Award	12,836	—	44,235
Schlichting Nancy M	director	2026-05-05	A-Award	12,836	—	34,994
Morrison Patricia	director	2026-05-05	A-Award	12,836	—	42,386
Shafer David Brent	director, other: Chair of the Board	2026-05-05	A-Award	12,836	—	72,804
Mcdonnell Michael R.	director	2026-05-05	A-Award	12,836	—	14,647

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
F — Tax withholding	10	93,403	$2.1M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalComp-Plan Activity Only

Open-Market Sells$0.0M0 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-05-18	Stephen N. Oesterle Rev Trust	36,347	$0.6M
2024-09-16	Stevens Brian	976	$0.0M
2024-09-13	Stevens Brian	16,063	$0.6M
2024-03-01	Jeanne Mason	64,488	$2.6M
Trailing 12 mo	1 filings	36,347	$1M

Filed	Form	Reporting person	% of class	Shares
2026-06-05	SCHEDULE 13G/A	Abigail P. Johnson	10.30%	53.0M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.36%	38.0M sh
2026-04-27	SCHEDULE 13G/A	BlackRock, Inc.	6.40%	33.1M sh
2026-04-21	SCHEDULE 13G/A	PZENA INVESTMENT MANAGEMENT LLC	12.70%	65.3M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-05-01	2026-06-11
Michael McCaul	House	BUY	$15,001 - $50,000	2026-03-23	2026-04-10
Michael T. McCaul	House	BUY	$15,001 - $50,000	2026-03-23	2026-04-10
Dan Sullivan	Senate	SELL	$1,001 - $15,000	2022-11-30	2023-07-26
Dan Sullivan	Senate	SELL	$1,001 - $15,000	2022-11-30	2023-07-25
Daniel Scott Sullivan	Senate	SELL	$1,001 - $15,000	2022-11-30	2023-07-25

House 12-Mo18 trades12 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)665

13F Shares529M102.3% of shares out

New / Closed83 / 118positions, QoQ

Increased / Reduced192 / 261positions, QoQ

Put/Call (13F)0.73option positions

Free Float99.4%514M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Wedge Capital Management L L P/Nc	1.1M	$26M
Auto-Owners Insurance Co	1.1M	$25M
O'Keefe Stevens Advisory, Inc.	719,676	$17M
Continental Advisors Llc	232,127	$6M
Wealth Enhancement Advisory Servic	191,603	$4M
Lipe & Dalton	170,483	$4M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$395M
VSMPX	0.0%	$395M
VTI	0.0%	$395M
VTSAX	0.0%	$395M
VFINX	0.0%	$326M
VFIAX	0.0%	$326M

13F Filers Holding BAX — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session55.1%2026-10-15

20-Day Avg51.9%50-day 52.1%

TrendFalling20d vs 50d

By Market CenterQ: 55% · N: 71% · B: 42%latest session

Weekly Notional ($B)

Where BAX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	8.6M	97 sh
Ebxl Level Ats	7.0M	55 sh
Ubsa Ubs Ats	6.2M	88 sh
Mstx Ms Trajectory Cross (Ats-1)	6.1M	121 sh
Sgmt Sigma X2	3.7M	102 sh
Mlix Instinct X	3.6M	135 sh

Where a dollar of Baxter International Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$6.1B	54%
Western Europe, Canada, Japan, Australia and New Zealand	$3.7B	33%
EMEA	$1.4B	12%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

BAX (live moat model)Peer median: SOLV · RGEN · AVTR · COO · HOLX

Component scores from the live moat model. Peer median illustrative.

Moat score 34/100 — None; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Andrew Hider	Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director
John Terence Rogers	Executive Vice President & Chief Financial Officer
Cynthia Carlisle	Executive Vice President & Chief Human Resources Officer
David S. Rosenbloom	Executive Vice President & General Counsel

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+13.1%

Next Report2026-10-29

Income QualityN/Mloss-making — OCF ÷ net income not meaningful

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+4.1%	-17.2%	+3.0%	+2.7%	+5.7%
Gross profit	+2.9%	-24.8%	+16.9%	-4.0%	-15.2%
Operating income	-16.5%	-310.7%	-124.9%	-98.0%	-2300.0%
Net income	+16.5%	-289.5%	-209.2%	-124.4%	+47.5%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	12.1	10.1	10.4	10.6	11.2
Cost of revenue	7.4	6.5	6.2	6.7	7.9
Gross profit	4.7	3.5	4.2	4.0	3.4
R&D expense	0.5	0.5	0.5	0.6	0.5
SG&A expense	2.8	3.1	3.0	3.0	2.9
Operating income	1.4	-2.8	0.7	0.0	-0.3
EBITDA	2.2	-1.8	1.7	1.1	0.8
D&A	0.9	1.1	1.0	1.0	1.0
Pretax income	1.1	-3.2	0.2	-0.3	-0.5
Income tax	0.1	-0.1	0.1	0.0	0.4
Net income	1.3	-2.4	2.7	-0.6	-1.0
Diluted EPS ($)	2.53	-4.83	5.23	-1.27	-1.75
Diluted shares (M)	508	504	506	510	513

Operating CF$1B

CapEx$1B

Free cash flow$0B

SBC$0B

Buybacks$0B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.7	3.1	1.8	2.0
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	2.6	1.8	1.7	1.9
Total current assets	8.0	9.6	8.9	6.9
PP&E (net)	5.2	3.2	3.2	3.2
Goodwill + intangibles	13.2	11.7	10.5	9.3
Total assets	28.3	28.3	25.8	20.1
Accounts payable	1.1	0.9	1.0	1.0
Short-term debt	1.4	2.7	2.8	0.1
Deferred revenue	0.2	0.1	0.1	0.1
Total current liabilities	4.7	6.5	6.5	3.0
Long-term debt	15.2	11.1	10.4	9.7
Total liabilities	22.4	19.8	18.8	14.0
Shareholders' equity	5.9	8.5	7.0	6.1

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	(3.1)	0.2	(0.3)	(1.0)
D&A	1.1	1.0	1.0	1.0
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.6)	0.2	(0.2)	(0.1)
Operating cash flow	1.2	1.7	1.0	0.8
Capital expenditures	(0.6)	(0.4)	(0.5)	(0.5)
Investing cash flow	(0.9)	3.2	(0.6)	2.8
Buybacks	(0.0)	0.0	0.0	0.0
Dividends paid	(0.6)	(0.6)	(0.6)	(0.3)
Debt issuance / (repay)	(0.9)	(2.9)	(0.5)	(3.8)
Financing cash flow	(1.4)	(3.5)	(1.1)	(4.2)
Free cash flow	0.6	1.3	0.6	0.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	14.5%	-32.6%	37.3%	-8.4%	-14.6%	-17%
ROA	4.8%	-7.9%	9.4%	-2.4%	-4.2%	-5.4%
ROIC	6.1%	-7.8%	-2.0%	0.1%	-1.7%	-1.6%
Gross margin	38.9%	35.3%	40.1%	37.5%	30.1%	30.1%
Operating margin	11.1%	-28.3%	6.8%	0.1%	-2.7%	-2.4%
Net margin	10.6%	-24.2%	25.6%	-6.1%	-8.5%	-9.3%
EBITDA margin	18.0%	-17.5%	16.7%	10.5%	6.8%	6.5%
FCF margin	11.6%	3.9%	8.7%	5.3%	2.9%	—
VALUATION
P/E	30.89	-9.85	7.05	-22.51	-10.26	-12.4
P/B	4.37	4.11	2.23	2.10	1.60	2.1
P/S	3.10	1.62	1.37	1.37	0.87	1.14
P/FCF	26.82	41.83	15.70	26.13	30.41	19.3
EV/EBITDA	21.38	-55.96	17.61	26.53	23.32	27.4
EV/Revenue	4.30	2.67	2.17	2.47	1.59	1.8
Earnings yield	3.2%	-10.2%	14.2%	-4.4%	-9.7%	-8.13%
FCF yield	3.7%	2.4%	6.4%	3.8%	3.3%	5.19%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	2.09	1.69	1.48	1.36	2.31	1.95
Quick ratio	1.52	1.12	1.18	1.05	1.56	1.32
Debt / equity	2.02	2.95	1.68	1.93	1.63	1.56
Debt / assets	54.6%	60.8%	49.9%	52.2%	49.9%	48.8%
Net debt / EBITDA	5.97	-21.96	6.53	11.79	10.49	10.02
Interest coverage	8.17	-5.04	1.26	0.29	-0.74	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.48	0.48	0.48	0.39	0.49	0.58
Receivables turnover	5.52	5.69	6.39	6.26	6.23	6.2
DSO (days)	66	64	57	58	59	59
DPO (days)	54	45	41	51	46	47
Cash conversion cycle	116	117	111	116	113	115
GROWTH (YoY)
Revenue growth	9.5%	15.7%	-7.4%	-22.4%	5.7%	—
Net income growth	16.5%	-289.5%	209.2%	-124.4%	-47.5%	—
EPS growth	18.6%	-289.5%	209.2%	-124.3%	-46.3%	—
FCF growth	27.6%	-61.3%	108.0%	-53.1%	-42.2%	—
PER SHARE ($)
EPS (diluted, TTM)	2.53	-4.80	5.24	-1.27	-1.86	-2.06
Book value / share	17.90	11.50	16.57	13.65	11.92	11.95
Revenue / share	25.21	29.19	27.03	20.85	21.88	22.19
FCF / share	2.92	1.13	2.35	1.10	0.63	1.31
Cash / share	5.82	3.39	6.07	3.46	3.82	4.16
SHAREHOLDER RETURN & SCORES
Buyback yield	1.5%	0.1%	0.0%	0.0%	0.0%	—
Altman Z-Score	2.40	1.76	2.06	1.81	2.14	2.3
Piotroski F-Score	5	4	6	2	5	4/9
Beneish M-Score	-1.97	-3.14	-2.63	-2.71	-2.48	-2.98

Model	Score	Zone	Note
Piotroski F-Score	4 / 9	Middling
Altman Z-Score	2.3	Grey zone	Grey
Income quality	N/M	Loss-making	OCF ÷ net income not meaningful with negative earnings; OCF itself is the signal
Beneish M-Score	-2.98	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	2.20
Interest burden	2.38
Operating margin	-1.8%
Asset turnover	0.56×
Financial leverage	3.02×
= ROE	-16%

Growth Quality (live)	Value
Revenue stability	0.21
Earnings stability	0.07
Earnings persistence	0.50
Revenue CAGR 3y	-8.0%
EPS CAGR 3y	—
FCF CAGR 3y	-7.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.00%

Dividend Yield0.16%

Total Shareholder Return1.39%cash yield

SBC / Revenue1.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
SOLV	$14.6B	10.4	34%	4.2%	-0.9%	7/9	+20.1%
RGEN	$11.1B	237.1	2%	2.5%	+16.5%	8/9	+13.5%
AVTR	$11.1B	-19.6	-10%	2.3%	-1.6%	6/9	+12.7%
COO	$11.0B	19.8	7%	40.6%	+4.7%	6/9	-19.0%
HOLX	$17.0B	30.3	11%	17.1%	+2.2%	6/9	—
ATR	$7.9B	22.2	14%	8.5%	+8.9%	6/9	—
WST	$27.0B	48.8	19%	17.7%	+12.4%	9/9	—
BLCO	$5.9B	-34.5	-3%	-1.0%	+8.8%	5/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

36 Analysts

Str Sell (0)Sell (1)Hold (20)Buy (15)Str Buy (0)

Mean Target (qtr)$24.254 targets

Target vs. Price-4.1%last-quarter mean

Next Report2026-10-29street $0.52

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$11.62B	$11.65B / $11.59B	$2.05	$2.08 / $1.98	9
FY2027	$11.87B	$11.94B / $11.76B	$2.04	$2.17 / $1.71	9
FY2028	$12.15B	$12.25B / $12.03B	$2.17	$3.10 / $1.44	3

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$20.00	-20.9%	1
Last Quarter	$24.25	-4.1%	4
Last Year	$22.32	-11.7%	19
All Time	$44.78	+77.1%	41

Rolling mean of published targets vs. last close $25.28. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C

DCF

4/5

ROE

1/5

ROA

1/5

Debt/Eq

1/5

P/E

1/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

BAX +10.3% vs S&P 500 +15.9% — spread -5.6pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$24.07	+1.21	+5.03%	Above
SMA 50	$25.00	+0.28	+1.12%	Above
SMA 200	$21.09	+4.19	+19.87%	Above
EMA 9	$24.79	+0.49	+1.98%	Above
EMA 21	$24.45	+0.83	+3.39%	Above
EMA 50	$24.29	+0.99	+4.08%	Above
EMA 200	$22.69	+2.59	+11.41%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6219 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%82

Volume 20%75

Volatility 10%100

Patterns 15%38

This Week100% bullishof 11 price-based votes

4 Weeks Ago18%+82 pts since

12 Weeks Ago45%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$24.07

Price vs SMA 50$25.00

Price vs SMA 200$21.09

EMA 9/21 Cross24.8/24.4

SMA 50/200Golden

ADX DirectionADX 24

Supertrend$23

Parabolic SAR$24

SMA Slope0.120

RSI59.5

Stochastic K/D83/85

StochRSI K/D89/95

Williams %R-25

CCI167

TSI vs Signal8.4

CMO18.9

ROC7.62%

OBV SignalDistrib

Chaikin MF0.130

MFI51

Force Index1M

Elder Ray Bull1.54

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 85

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$25.62 / $26.03 / $26.29	S1 / S2	$25.36 / $24.95
Bollinger (20,2)	$22.65 – $25.49	Squeeze	Off
52-wk range	$15.71 – $29.99	Off 52-wk high	-15.7%
ATR (14)	$0.72 (2.8%)	Historical vol	26.3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.2%Jan55%

+0.3%Feb55%

+1.2%Mar67%

+0.2%Apr50%

-1.9%May45%

+1.4%Jun55%

+0.5%Jul65%

+0.6%Aug50%

-0.7%Sep55%

-2.6%Oct40%

+0.3%Nov50%

+1.5%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	BAX	S&P 500
Weekly volatility (σ, 1y)	5.77%	1.83%
Best / worst week (1y)	+13.9% / -16.7%	—
Max drawdown (5y, monthly)	-80.7%	—
1-week VaR (95%)	-7.9%	—
Beta (5y)	0.59	1.00

BAX EQUITY WEATHER (LIVE)PARTLY CLOUDY · +19

Trend+39

Momentum+50

Volume+33

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 86 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+18.9+29.2 vs industry

Trend+39.2+38.5 vs industry

Momentum+50.2+51.3 vs industry

Volume+33.1+16.0 vs industry

Reading	BAX	Medical - Instruments & Supplies n=284	Healthcare n=5,272	All US symbols n=70,435
Overall	+18.9	-10.3	-24.0	-20.5
Trend	+39.2	+0.7	-25.6	-21.3
Momentum	+50.2	-1.1	-28.5	-15.8
Volume	+33.1	+17.1	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Joel Grade Former Executive Vice President a	$8.2M	76% equity+incentive
José E. Almeida Former Chair of the Board, P	$7.7M	0% equity+incentive
Reazur Rasul Executive Vice President and Gr	$5.2M	66% equity+incentive
Alok Sonig Former Executive Vice President a	$5.2M	64% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	81
Social	64
Governance	74
Composite ESG	73

Composite ESG Trend

Filed	8-K contents	Items
2026-08-19	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-08-18	Material Agreement; Other Events; Exhibits	1.01,8.01,9.01
2026-08-04	Other Events; Exhibits	8.01,9.01
2026-08-04	Officer/Director Change	5.02
2026-07-30	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-07-14	Regulation FD; Exhibits	7.01,9.01
2026-05-08	Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits	5.02,5.03,5.07,9.01
2026-04-30	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-07-30
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-04-01 to 2026-09-02
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-04-21 to 2026-06-05
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Baxter International Inc. (BAX)

Institutions holding — 12 quarters

Baxter International Inc. (BAX)

Monthly Net Insider Flow (000 shares)

Signal Summary

Baxter International Inc. (BAX)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding BAX — quarterly

Institutional Put/Call — quarterly

Baxter International Inc. (BAX)

Where BAX Trades in the Dark

Baxter International Inc. (BAX)

3.8 · Employees (SEC filings)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Balance Sheet — Full

Cash Flow Statement — Full

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Street Price Target — Trajectory

Third-Party Composite Rating

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Family Scores (site weights)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)

Baxter International Inc. (BAX)